EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice

Marwa Al-Badri iD, Shilton Dhaver iD, Osama Hamdy

Journal of Diabetes · 2025

DOI: 10.1111/1753-0407.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes, 2025. Verfasst von Marwa Al-Badri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Joslin Diabetes Center, Affiliated With Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Weight Loss, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are established treatment options for type 2 diabetes (T2D). In addition to their glycemic benefit, GLP‐1 RAs also induce weight loss by suppressing appetite via hypothalamic pathways. However, it remains unclear whether weight reduction is the primary driver of glycemic improvement.

Methods

We retrospectively evaluated 256 patients with T2D who were treated with exenatide ( n = 84), dulaglutide ( n = 99), or semaglutide ( n = 73) for 2.5 years without interruption in real‐world clinical practice. Body weight and A1C were measured every 6 months. Baseline characteristics included an average age of 61.8 ± 11.9 years, 51.5% female, diabetes duration of 12.9 ± 8.3 years, weight of 103.1 ± 20.7 kg, BMI of 35.7 ± 7.5 kg/m 2 , and A1C of 8.2% ± 1.5%. Patients were stratified into tertiles based on percentage weight change at 2.5 years within the overall cohort and for each GLP‐1 RA group.

Results

The first tertile experienced an average weight loss of −12.2% ± 5.7% ( p < 0.0001), the second tertile lost −3.5% ± 1.4% ( p < 0.0001), and the third tertile gained +2.8% ± 3.4% ( p < 0.0001). The average changes in A1C were − 0.98 ± 1.8% ( p < 0.0001), −0.56% ± 1.4% ( p < 0.001), and −0.19% ± 1.9% ( p = 0.4), respectively. A1C strongly correlated with weight change ( p < 0.001). The same observations were reproducible in each medication group.

Conclusions

These findings suggest that the long‐term improvement in glycemic control associated with GLP‐1 RA therapy is primarily driven by weight loss rather than any other intrinsic effect of GLP‐1 RA. This highlights the importance of weight reduction as a key therapeutic target for optimizing glycemic outcomes in patients with T2D receiving GLP‐1 RAs. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsHumansFemaleMiddle AgedMaleRetrospective StudiesGlucagon-Like PeptidesExenatideImmunoglobulin Fc FragmentsAgedBlood GlucoseRecombinant Fusion ProteinsTreatment OutcomeGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 receptor agonistsglycemic controlreal‐world clinical practicetype 2 diabetesweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsGlucagon-Like PeptidesExenatideImmunoglobulin Fc FragmentsBlood GlucoseRecombinant Fusion ProteinsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Joslin Diabetes Center, Affiliated With Harvard Medical School, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Marwa Al-Badri, Shilton Dhaver

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Al-Badri, M., Dhaver, S., & Hamdy, O. (2025). Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70054

Vancouver

Al-Badri M, Dhaver S, Hamdy O. Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice. Journal of Diabetes. 2025. doi:10.1111/1753-0407.70054

BibTeX
@article{AlBadri2025,
  author = {Al-Badri, Marwa and Dhaver, Shilton and Hamdy, Osama},
  title = {Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 ( GLP ‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice},
  journal = {Journal of Diabetes},
  year = {2025},
  doi = {10.1111/1753-0407.70054}
}
Kostenlos starten →